HQE1 Stock Overview
Engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Cytosorbents Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.79 |
| 52 Week High | US$1.36 |
| 52 Week Low | US$0.62 |
| Beta | 1.18 |
| 1 Month Change | -6.41% |
| 3 Month Change | -16.17% |
| 1 Year Change | -0.13% |
| 3 Year Change | -54.36% |
| 5 Year Change | -91.70% |
| Change since IPO | -79.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| HQE1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -15.5% | 1.7% | 3.4% |
| 1Y | -0.1% | -11.2% | 15.0% |
Return vs Industry: HQE1 exceeded the German Medical Equipment industry which returned -11.3% over the past year.
Return vs Market: HQE1 underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| HQE1 volatility | |
|---|---|
| HQE1 Average Weekly Movement | 12.9% |
| Medical Equipment Industry Average Movement | 5.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: HQE1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: HQE1's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 149 | Phil Chan | www.cytosorbents.com |
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood.
Cytosorbents Corporation Fundamentals Summary
| HQE1 fundamental statistics | |
|---|---|
| Market cap | €51.91m |
| Earnings (TTM) | -€18.31m |
| Revenue (TTM) | €31.45m |
1.6x
P/S Ratio-2.7x
P/E RatioIs HQE1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HQE1 income statement (TTM) | |
|---|---|
| Revenue | US$35.59m |
| Cost of Revenue | US$10.47m |
| Gross Profit | US$25.13m |
| Other Expenses | US$45.84m |
| Earnings | -US$20.72m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 14, 2025
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 70.59% |
| Net Profit Margin | -58.21% |
| Debt/Equity Ratio | 126.0% |
How did HQE1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 10:37 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cytosorbents Corporation is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Aschoff | Brean Capital |
| Jason Kolbert | D. Boral Capital LLC. |
| Sean Lee | H.C. Wainwright & Co. |